Human

Antibodies sourced from human donors

Antibodies sourced from human donors

AIMM has successfully exploited its AIMSelect™ platform to immortalize human antibody–producing B cells covering the complete B cell antibody repertoire including all isotypes and immature, switched and hypermutated cells.

Using the platform, antibodies with promising therapeutic potential have already been isolated from individuals in remission from cancer and those who have successfully recovered from infectious diseases. Two antibodies are currently in clinical development.